Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD109 Continuation Protocol in OSA
NCT06566820Phase 3Enrolling by invitation
- Sponsor
- Apnimed, Inc.
- Start
- Jul 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of oxybutynin, atomoxetine in obstructive sleep apnea (OSA), sponsored by Apnimed, Inc.. Started Jul 2024; status: enrolling by invitation.
02
Drugs
oxybutyninatomoxetine
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT06566820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06566820.